Lilly, Strides Arcolab target cut-price cancer meds at growth markets December 5, 2012 | By Eric Palmer While growth in emerging markets is enticing to Big Pharma, patients and governments often lack the wherewithal to pay for expensive drugs, making price point particularly important. Eli Lilly ($LLY) is joining the trend of picking a low-cost partner with the expectation that it can more easily reach that sweet spot. Lilly and Indian generics maker Strides Arcolab have struck a deal for Strides' injectable drugs subsidiary Agila Specialties to manufacture 10 Lilly branded generic cancer drugs for India and other emerging markets. If Lilly likes how that works, it has an option to pile some more into the portfolio, Reuters explains. "Cancer medicines of the highest quality continue to be an unmet need in many markets around the world," Jacques Tapiero, senior vice president and president, emerging markets at Eli Lilly, said in a statement. Consultant IMS Health forecasts that annual drug spending could account for 28% of global sales by 2015, up dramatically from 12% in 2005. But sales in these markets are not as easy to come by as they are in Western markets where health programs and high standards of living make drug purchases a matter of everyday life. India and China, two of the largest emerging markets, have lists of essential medicines on which they put price caps. China recently slashed prices on 95 drugs--including cancer and immune-system treatments--by an average of 17%. And India is looking at placing 348 generic drugs under new price caps, up from just 74 today. Some Big Pharma companies are attacking the challenge by forming partnerships with local producers with lower production costs as well as ties to local markets. Gilead Sciences ($GILD), which produces some of the most effective but priciest HIV-fighting treatments, recently struck just such a deal with three companies, including Strides Arcolab. The agreements include Gilead's Emtriva (emtricitabine) and the combo drug Truvada, which recently won FDA approval for preventing HIV infection. Indian generics giant Ranbaxy Laboratories as well as U.S. generics maker Mylan ($MYL), round out that manufacturing pact. The companies are aiming for high-volume production at reduced cost so that prices can be lowered.
礼来与印度Strides合作扩大新兴市场存在发布时间：2012-12-7 来源：药品资讯网信息中心 印度Strides Arcolab与礼来(Eli Lilly)周三宣布，双方已达成了一项协议，将共同生产并在发展中国家市场销售抗癌防制药。此举意在扩大礼来在新兴市场中的存在。根据协议，礼来授权获得Strides Arcolab旗下Agila Specialties公司的一组高质量的口服及注射抗癌仿制药，Agila Specialties将负责生产这些仿制药，礼来则负责多个新兴市场中的注册及销售。这是大型制药公司寻求在新兴市场取得更多增长所达成一系列协议的最新协议，同时印度制药公司也在寻找全球性的合作伙伴。该项协议，将以10种药品开始，礼来保留在未来增加药物数量的权利。根据IMS数据，2012~2016年新兴市场中年度药品支出预计将增加12~15%，在全球销售中的比例，将从2005年的12%上升至2015年的28%。高质量的抗癌药物，将继续成为全球各地市场中未获满足的需求，礼来在声明中说道。
